Towards combinatorial targeted therapy in melanoma: From pre-clinical evidence to clinical application (Review)

International Journal of Oncology

Volumn 45, Issue 3, 2014, Pages 929-949

  Grazia, Giulia ^a   Penna, Ilaria ^a   Perotti, Valentina ^a   Anichini, Andrea ^a   Tassi, Elena ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Apoptosis; Combinatorial treatment; Melanoma; Targeted therapy

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AZD 8055; BEVACIZUMAB; BORTEZOMIB; BUPARLISIB; COBIMETINIB; DABRAFENIB; DACTOLISIB; DASATINIB; EVEROLIMUS; IMATINIB; LONAFARNIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PACLITAXEL; PICTILISIB; PIMASERTIB; RAPAMYCIN; RO 5068760; SELUMETINIB; SORAFENIB; TRAMETINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ANGIOGENESIS; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AUTOPHOSPHORYLATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CAPPING PHENOMENON; CELL DEATH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COLONY FORMATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IN VITRO STUDY; LIGAND BINDING; MANTLE CELL LYMPHOMA; MELANOMA; MELANOMA CELL LINE; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; UPREGULATION; UVEA MELANOMA; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GENETICS; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84904394543     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2491     Document Type: Review

References (179)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Jilaveanu LB, Aziz SA and Kluger HM: Chemotherapy and biologic therapies for melanoma: do they work? Clin Dermatol 27: 614-625, 2009.
3. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002. (Pubitemid 34716871)
4. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819, 2010.
5. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011.
6. Hauschild A, Grob JJ, Demidov LV, et al: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358-365, 2012.
7. Flaherty KT, Robert C, Hersey P, et al: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367: 107-114, 2012.
8. Sosman JA, Kim KB, Schuchter L, et al: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 707-714, 2012.
9. Aplin AE, Kaplan FM and Shao Y: Mechanisms of resistance to RAF inhibitors in melanoma. J Invest Dermatol 131: 1817-1820, 2011.
10. Lito P, Rosen N and Solit DB: Tumor adaptation and resistance to RAF inhibitors. Nat Med 19: 1401-1409, 2013.
11. Nikolaou VA, Stratigos AJ, Flaherty KT and Tsao H: Melanoma: new insights and new therapies. J Invest Dermatol 132: 854-863, 2012.
12. Cragg MS, Jansen ES, Cook M, Harris C, Strasser A and Scott CL: Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 118: 3651-3659, 2008.
13. Jiang CC, Lai F, Tay KH, et al: Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis 1: e69, 2010.
14. Eberle J, Fecker LF, Hossini AM, Kurbanov BM and Fechner H: Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma. Exp Dermatol 17: 1-11, 2008. (Pubitemid 350269205)
15. Wang X: The expanding role of mitochondria in apoptosis. Genes Dev 15: 2922-2933, 2001.
16. Guicciardi ME and Gores GJ: Life and death by death receptors. FASEB J 23: 1625-1637, 2009.
17. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S and Korneluk RG: IAP-targeted therapies for cancer. Oncogene 27: 6252-6275, 2008.
18. Santarpia L, Lippman SM and El-Naggar AK: Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 16: 103-119, 2012.
19. Liu P, Cheng H, Roberts TM and Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8: 627-644, 2009.
20. Pickup M, Novitskiy S and Moses HL: The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer 13: 788-799, 2013.
21. Ara T and Declerck YA: Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 46: 1223-1231, 2010.
22. Crowe DL and Shuler CF: Regulation of tumor cell invasion by extracellular matrix. Histol Histopathol 14: 665-671, 1999. (Pubitemid 29159034)
23. Fedorenko IV, Gibney GT and Smalley KS: NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene 32: 3009-3018, 2013.
24. Shi H, Hong A, Kong X, et al: A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov 4: 69-79, 2013.
25. Davies MA, Stemke-Hale K, Tellez C, et al: A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 99: 1265-1268, 2008.
26. Aguissa-Toure AH and Li G: Genetic alterations of PTEN in human melanoma. Cell Mol Life Sci 69: 1475-1491, 2012.
27. McCubrey JA, Steelman LS, Kempf CR, et al: Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol 226: 2762-2781, 2011.
28. Easty DJ, Gray SG, O'Byrne KJ, O'Donnell D and Bennett DC: Receptor tyrosine kinases and their activation in melanoma. Pigment Cell Melanoma Res 24: 446-461, 2011.
29. Straussman R, Morikawa T, Shee K, et al: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487: 500-504, 2012.
30. Lippitz BE: Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 14: e218-228, 2013.
31. Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11-22, 2003.
32. Populo H, Lopes JM and Soares P: The mTOR signalling pathway in human cancer. Int J Mol Sci 13: 1886-1918, 2012.
33. Mendoza MC, Er EE and Blenis J: The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36: 320-328, 2011.
34. Shi H, Kong X, Ribas A and Lo RS: Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 71: 5067-5074, 2011.
35. Britten CD: PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother Pharmacol 71: 1395-1409, 2013.
36. Bjornsti MA and Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335-348, 2004. (Pubitemid 38579480)
37. Hay N: The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8: 179-183, 2005.
38. Aziz SA, Jilaveanu LB, Zito C, et al: Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res 16: 6029-6039, 2010.
39. Werzowa J, Cejka D, Fuereder T, et al: Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002. Br J Dermatol 160: 955-964, 2009.
40. Marone R, Erhart D, Mertz AC, et al: Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol Cancer Res 7: 601-613, 2009.
41. Babchia N, Calipel A, Mouriaux F, Faussat AM and Mascarelli F: The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK. Invest Ophthalmol Vis Sci 51: 421-429, 2010.
42. Werzowa J, Koehrer S, Strommer S, et al: Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo. J Invest Dermatol 131: 495-503, 2011.
43. Smalley KS: Understanding melanoma signaling networks as the basis for molecular targeted therapy. J Invest Dermatol 130: 28-37, 2010.
44. Emery CM, Vijayendran KG, Zipser MC, et al: MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 106: 20411-20416, 2009.
45. Mitsiades N, Chew SA, He B, et al: Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. Invest Ophthalmol Vis Sci 52: 7248-7255, 2011.
46. Shao Y and Aplin AE: BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. Cell Death Differ 19: 2029-2039, 2012.
47. Carlino MS, Gowrishankar K, Saunders CA, et al: Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. Mol Cancer Ther 12: 1332-1342, 2013.
48. King AJ, Arnone MR, Bleam MR, et al: Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLoS One 8: e67583, 2013.
49. Greger JG, Eastman SD, Zhang V, et al: Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 11: 909-920, 2012.
50. Gadiot J, Hooijkaas AI, Deken MA and Blank CU: Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity. Onco Targets Ther 6: 1649-1658, 2013.
51. Su F, Bradley WD, Wang Q, et al: Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res 72: 969-978, 2012.
52. Park SJ, Hong SW, Moon JH, et al: The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells. Am J Med Sci 346: 494-498, 2013.
53. Nakamura A, Arita T, Tsuchiya S, et al: Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Res 73: 7043-7055, 2013.
54. Niessner H, Beck D, Sinnberg T, et al: The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. J Invest Dermatol 131: 468-479, 2011.
55. Baudy AR, Dogan T, Flores-Mercado JE, et al: FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJNMMI Res 2: 22-31, 2012.
56. Carracedo A, Ma L, Teruya-Feldstein J, et al: Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074, 2008.
57. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, et al: Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 118: 3051-3064, 2008.
58. Roberts PJ, Usary JE, Darr DB, et al: Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res 18: 5290-5303, 2012.
59. Ho AL, Musi E, Ambrosini G, et al: Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One 7: e40439, 2012.
60. Gopal YN, Deng W, Woodman SE, et al: Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70: 8736-8747, 2010.
61. Atefi M, von Euw E, Attar N, et al: Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One 6: e28973, 2011.
62. Ambrosini G, Musi E, Ho AL, de Stanchina E and Schwartz GK: Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. Mol Cancer Ther 12: 768-776, 2013.
63. Fowles JS, Denton CL and Gustafson DL: Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma. Vet Comp Oncol: Jun 7, 2013 (Epub ahead of print).
64. Meier F, Busch S, Lasithiotakis K, et al: Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol 156: 1204-1213, 2007. (Pubitemid 47029801)
65. Lasithiotakis KG, Sinnberg TW, Schittek B, et al: Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol 128: 2013-2023, 2008. (Pubitemid 352001225)
66. Dankort D, Curley DP, Cartlidge RA, et al: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41: 544-552, 2009.
67. Hoeflich KP, Merchant M, Orr C, et al: Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res 72: 210-219, 2012.
68. Tassi E, Zanon M, Vegetti C, et al: Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. Clin Cancer Res 18: 3316-3327, 2012.
69. Byron SA, Loch DC, Wellens CL, et al: Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. Mol Cancer 11: 75-89, 2012.
70. Khalili JS, Yu X, Wang J, et al: Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res 18: 4345-4355, 2012.
71. Choo EF, Ng CM, Berry L, et al: PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts. Cancer Chemother Pharmacol 71: 133-143, 2013.
72. Posch C, Moslehi H, Feeney L, et al: Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci USA 110: 4015-4020, 2013.
73. Ciuffreda L, Di Sanza C, Cesta Incani U, et al: The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. J Mol Med (Berl) 90: 667-679, 2012.
74. Bedogni B, O'Neill MS, Welford SM, et al: Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res 64: 2552-2560, 2004.
75. Bedogni B, Welford SM, Kwan AC, Ranger-Moore J, Saboda K and Powell MB: Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model. Mol Cancer Ther 5: 3071-3077, 2006. (Pubitemid 46092048)
76. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT and Herlyn M: Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5: 1136-1144, 2006. (Pubitemid 43881305)
77. Deng W, Gopal YN, Scott A, Chen G, Woodman SE and Davies MA: Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res 25: 248-258, 2012.
78. Jiang CC, Lai F, Thorne RF, et al: MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res 17: 721-730, 2011.
79. Molhoek KR, Brautigan DL and Slingluff CL Jr: Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med 3: 39-49, 2005.
80. Held MA, Langdon CG, Platt JT, et al: Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov 3: 52-67, 2013.
81. Boisvert-Adamo K and Aplin AE: B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis. Oncogene 25: 4848-4856, 2006. (Pubitemid 44201176)
82. Villanueva J, Infante JR, Krepler C, et al: Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep 4: 1090-1099, 2013.
83. Curtin JA, Busam K, Pinkel D and Bastian BC: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24: 4340-4346, 2006. (Pubitemid 46630793)
84. Ashida A, Takata M, Murata H, Kido K and Saida T: Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 124: 862-868, 2009.
85. Thomas RK, Baker AC, Debiasi RM, et al: High-throughput oncogene mutation profiling in human cancer. Nat Genet 39: 347-351, 2007. (Pubitemid 46328493)
86. Prickett TD, Agrawal NS, Wei X, et al: Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 41: 1127-1132, 2009.
87. Ruhe JE, Streit S, Hart S, et al: Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res 67: 11368-11376, 2007. (Pubitemid 350248564)
88. Gitay-Goren H, Halaban R and Neufeld G: Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun 190: 702-708, 1993.
89. Barnhill RL, Xiao M, Graves D and Antoniades HN: Expression of platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGF-alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivo. Br J Dermatol 135: 898-904, 1996. (Pubitemid 26397917)
90. Metzner T, Bedeir A, Held G, et al: Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. J Invest Dermatol 131: 2087-2095, 2011.
91. de Wit PE, Moretti S, Koenders PG, et al: Increasing epidermal growth factor receptor expression in human melanocytic tumor progression. J Invest Dermatol 99: 168-173, 1992.
92. Rakosy Z, Vizkeleti L, Ecsedi S, et al: EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int J Cancer 121: 1729-1737, 2007. (Pubitemid 47417290)
93. Reschke M, Mihic-Probst D, van der Horst EH, et al: HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 14: 5188-5197, 2008.
94. Ugurel S, Rappl G, Tilgen W and Reinhold U: Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19: 577-583, 2001. (Pubitemid 32112873)
95. Molhoek KR, Shada AL, Smolkin M, et al: Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R. Melanoma Res 21: 274-284, 2011.
96. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327-337, 2003. (Pubitemid 36109749)
97. Qin JZ, Ziffra J, Stennett L, et al: Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65: 6282-6293, 2005. (Pubitemid 40994414)
98. Fernandez Y, Verhaegen M, Miller TP, et al: Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 65: 6294-6304, 2005. (Pubitemid 40994415)
99. Markovic SN, Geyer SM, Dawkins F, et al: A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103: 2584-2589, 2005. (Pubitemid 40800538)
100. Yeramian A, Sorolla A, Velasco A, et al: Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway. Int J Cancer 130: 967-978, 2012.
101. Li J, Rix U, Fang B, et al: A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 6: 291-299, 2010.
102. Dewaele B, Floris G, Finalet-Ferreiro J, et al: Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. Cancer Res 70: 7304-7314, 2010.
103. Vultur A, Villanueva J, Krepler C, et al: MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines. Oncogene: Apr 29, 2013 (Epub ahead of print).
104. Hamai A, Richon C, Meslin F, et al: Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: relationship to Bcl-2 family and caspase activation. Oncogene 25: 7618-7634, 2006. (Pubitemid 44924475)
105. Klosowska-Wardega A, Hasumi Y, Ahgren A, Heldin CH and Hellberg C: Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor. Melanoma Res 21: 57-65, 2011.
106. Molhoek KR, Griesemann H, Shu J, Gershenwald JE, Brautigan DL and Slingluff CL Jr: Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res 68: 4392-4397, 2008.
107. O'Reilly T, Lane HA, Wood JM, et al: Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model. Cancer Chemother Pharmacol 67: 193-200, 2011.
108. Schicher N, Paulitschke V, Swoboda A, et al: Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res 15: 3495-3502, 2009.
109. Vergani E, Vallacchi V, Frigerio S, et al: Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia 13: 1132-1142, 2011.
110. Girotti MR, Pedersen M, Sanchez-Laorden B, et al: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov 3: 158-167, 2013.
111. Abel EV, Basile KJ, Kugel CH III, et al: Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest 123: 2155-2168, 2013.
112. Fattore L, Marra E, Pisanu ME, et al: Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. J Transl Med 11: 180-190, 2013.
113. Karasic TB, Hei TK and Ivanov VN: Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: a new potential therapy for the treatment of melanoma. Exp Cell Res 316: 1994-2007, 2010.
114. Villanueva J, Vultur A, Lee JT, et al: Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683-695, 2010.
115. Wehrli P, Viard I, Bullani R, Tschopp J and French LE: Death receptors in cutaneous biology and disease. J Invest Dermatol 115: 141-148, 2000. (Pubitemid 30637180)
116. Zhang XD, Franco A, Myers K, Gray C, Nguyen T and Hersey P: Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 59: 2747-2753, 1999. (Pubitemid 29269125)
117. Micheau O, Shirley S and Dufour F: Death receptors as targets in cancer. Br J Pharmacol 169: 1723-1744, 2013.
118. Roberts NJ, Zhou S, Diaz LA Jr and Holdhoff M: Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget 2: 739-751, 2011.
119. Etter AL, Bassi I, Germain S, et al: The combination of chemotherapy and intraperitoneal MegaFas ligand improves treatment of ovarian carcinoma. Gynecol Oncol 107: 14-21, 2007. (Pubitemid 47470085)
120. Gajewski TF: On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol 25: 1305-1307, 2007.
121. Duiker EW, Mom CH, de Jong S, et al: The clinical trail of TRAIL. Eur J Cancer 42: 2233-2240, 2006. (Pubitemid 44307615)
122. Zhang XD, Borrow JM, Zhang XY, Nguyen T and Hersey P: Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 22: 2869-2881, 2003. (Pubitemid 36648914)
123. Berger A, Quast SA, Plotz M, Kuhn NF, Trefzer U and Eberle J: RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells. J Invest Dermatol 134: 430-440, 2014.
124. Quast SA, Berger A and Eberle J: ROS-dependent phosphorylation of Bax by wortmannin sensitizes melanoma cells for TRAIL-induced apoptosis. Cell Death Dis 4: e839, 2013.
125. Phipps LE, Hino S and Muschel RJ: Targeting cell spreading: a method of sensitizing metastatic tumor cells to TRAIL-induced apoptosis. Mol Cancer Res 9: 249-258, 2011.
126. Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784, 2006.
127. Zhang XD, Gillespie SK, Borrow JM and Hersey P: The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol 66: 1537-1545, 2003.
128. Gillespie S, Borrow J, Zhang XD and Hersey P: Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells. Apoptosis 11: 2251-2265, 2006. (Pubitemid 44885400)
129. Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O and Engebraaten O: Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. J Gene Med 9: 440-451, 2007. (Pubitemid 46994573)
130. Perotti V, Baldassari P, Bersani I, et al: NFATc2 is a potential therapeutic target in human melanoma. J Invest Dermatol 132: 2652-2660, 2012.
131. Zimmerman ZF, Kulikauskas RM, Bomsztyk K, Moon RT and Chien AJ: Activation of Wnt/beta-catenin signaling increases apoptosis in melanoma cells treated with trail. PLoS One 8: e69593, 2013.
132. Berger A, Quast SA, Plotz M, Kammermeier A and Eberle J: Sensitization of melanoma cells for TRAIL-induced apoptosis by BMS-345541 correlates with altered phosphorylation and activation of Bax. Cell Death Dis 4: e477, 2013.
133. Lecis D, Drago C, Manzoni L, et al: Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. Br J Cancer 102: 1707-1716, 2010.
134. Baritaki S, Yeung K, Palladino M, Berenson J and Bonavida B: Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Cancer Res 69: 8376-8385, 2009.
135. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ and Borden EC: Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 11: 915-923, 2004.
136. Engesaeter BO, Sathermugathevan M, Hellenes T, et al: Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells. Cancer Biol Ther 12: 47-58, 2011.
137. Chetoui N, Sylla K, Gagnon-Houde JV, et al: Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis. Mol Cancer Res 6: 42-52, 2008.
138. Safa AR: c-FLIP, a master anti-apoptotic regulator. Exp Oncol 34: 176-184, 2012.
139. Geserick P, Drewniok C, Hupe M, et al: Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene 27: 3211-3220, 2008.
140. Hartman ML and Czyz M: Anti-apoptotic proteins on guard of melanoma cell survival. Cancer Lett 331: 24-34, 2013.
141. Oltersdorf T, Elmore SW, Shoemaker AR, et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681, 2005. (Pubitemid 40825512)
142. Hann CL, Daniel VC, Sugar EA, et al: Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 68: 2321-2328, 2008. (Pubitemid 351521806)
143. Wroblewski D, Mijatov B, Mohana-Kumaran N, et al: The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. Carcinogenesis 34: 237-247, 2013.
144. VanBrocklin MW, Verhaegen M, Soengas MS and Holmen SL: Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. Cancer Res 69: 1985-1994, 2009.
145. Tse C, Shoemaker AR, Adickes J, et al: ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68: 3421-3428, 2008.
146. Sale MJ and Cook SJ: The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. Biochem J 450: 285-294, 2013.
147. Verhaegen M, Bauer JA, Martin de la Vega C, et al: A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 66: 11348-11359, 2006. (Pubitemid 46009966)
148. Senft D, Berking C, Graf SA, Kammerbauer C, Ruzicka T and Besch R: Selective induction of cell death in melanoma cell lines through targeting of Mcl-1 and A1. PLoS One 7: e30821, 2012.
149. Haq R, Yokoyama S, Hawryluk EB, et al: BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci USA 110: 4321-4326, 2013.
150. Koul HK, Pal M and Koul S: Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer 4: 342-359, 2013.
151. Keuling AM, Andrew SE and Tron VA: Inhibition of p38 MAPK enhances ABT-737-induced cell death in melanoma cell lines: novel regulation of PUMA. Pigment Cell Melanoma Res 23: 430-440, 2010.
152. Boyle GM, Martyn AC and Parsons PG: Histone deacetylase inhibitors and malignant melanoma. Pigment Cell Res 18: 160-166, 2005.
153. Kortylewski M, Jove R and Yu H: Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 24: 315-327, 2005.
154. Qin JZ, Xin H, Sitailo LA, Denning MF and Nickoloff BJ: Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Res 66: 9636-9645, 2006. (Pubitemid 44623663)
155. Wolter KG, Verhaegen M, Fernandez Y, et al: Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ 14: 1605-1616, 2007.
156. Nguyen M, Marcellus RC, Roulston A, et al: Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 104: 19512-19517, 2007.
157. Freudlsperger C, Thies A, Pfuller U and Schumacher U: The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells. Anticancer Res 27: 207-213, 2007.
158. Miller LA, Goldstein NB, Johannes WU, et al: BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. J Invest Dermatol 129: 964-971, 2009.
159. Reuland SN, Goldstein NB, Partyka KA, et al: ABT-737 synergizes with Bortezomib to kill melanoma cells. Biol Open 1: 92-100, 2011.
160. Mlynarczuk-Bialy I, Roeckmann H, Kuckelkorn U, et al: Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells. Cancer Res 66: 7598-7605, 2006.
161. Millward M, Price T, Townsend A, et al: Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs 30: 2303-2317, 2012.
162. Lai F, Guo ST, Jin L, et al: Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. Cell Death Dis 4: e655, 2013.
163. Niu G, Wright KL, Huang M, et al: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008, 2002. (Pubitemid 34270888)
164. van Delft MF, Wei AH, Mason KD, et al: The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10: 389-399, 2006.
165. Konopleva M, Contractor R, Tsao T, et al: Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10: 375-388, 2006. (Pubitemid 44693472)
166. Keuling AM, Felton KE, Parker AA, Akbari M, Andrew SE and Tron VA: RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway. PLoS One 4: e6651, 2009.
167. Lucas KM, Mohana-Kumaran N, Lau D, et al: Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Clin Cancer Res 18: 783-795, 2012.
168. Pandey MK, Gowda K, Doi K, Sharma AK, Wang HG and Amin S: Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells. PLoS One 8: e78570, 2013.
169. Davies MA, Fox PS, Papadopoulos NE, et al: Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res 18: 1120-1128, 2012.
170. Margolin KA, Moon J, Flaherty LE, et al: Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res 18: 1129-1137, 2012.
171. Hong DS, Sebti SM, Newman RA, et al: Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res 15: 7061-7068, 2009.
172. Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367: 1694-1703, 2012.
173. Su F, Viros A, Milagre C, et al: RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366: 207-215, 2012.
174. Hainsworth JD, Infante JR, Spigel DR, et al: Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 116: 4122-4129, 2010.
175. Slingluff CL Jr, Petroni GR, Molhoek KR, et al: Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47). Clin Cancer Res 19: 3611-3620, 2013.
176. Vaishampayan UN, Burger AM, Sausville EA, et al: Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin. Clin Cancer Res 16: 3795-3804, 2010.
177. Vanneman M and Dranoff G: Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12: 237-251, 2012.
178. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723, 2010.
179. Hamid O, Robert C, Daud A, et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369: 134-144, 2013.